Vertex Pharmaceuticals (VRTX) to Release Quarterly Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) will post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect Vertex Pharmaceuticals to post earnings of $3.61 per share for the quarter. Vertex Pharmaceuticals has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the previous year, the firm posted $3.33 earnings per share. On average, analysts expect Vertex Pharmaceuticals to post $15 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $401.08 on Friday. The company has a market capitalization of $103.66 billion, a P/E ratio of 28.88, a P/E/G ratio of 1.89 and a beta of 0.39. The business’s 50-day moving average is $409.64 and its two-hundred day moving average is $399.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. Vertex Pharmaceuticals has a fifty-two week low of $320.01 and a fifty-two week high of $448.40.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, CAO Kristen Ambrose sold 1,374 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $577,409.76. Following the sale, the chief accounting officer now owns 9,676 shares in the company, valued at $4,066,242.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Vertex Pharmaceuticals news, CAO Kristen Ambrose sold 1,374 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $577,409.76. Following the sale, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at $4,066,242.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares in the company, valued at approximately $11,596,934.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,381 shares of company stock worth $5,203,249. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on VRTX shares. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target for the company in a report on Thursday, April 11th. Maxim Group lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, UBS Group cut their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $430.86.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.